Bioprogress BPRG - Serious Investors Only (Moderated)

Press release from Inyx:



Inyx and BioProgress Form Strategic Collaboration



NEW YORK, Dec. 21 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin
Board: IYXI), a specialty pharmaceutical company focused on niche
drug-delivery technologies and products, announced today that its wholly
owned, United Kingdom-based subsidiary, Inyx Pharma Limited, has entered
into a strategic collaboration with BioProgress plc (Nasdaq and AIM: BPRG),
an innovative specialty pharma and healthcare company with U.K.
headquarters in Cambridge, England.
Under the collaboration, Inyx will provide assistance to broadly
commercialize BioProgress' TABWRAP(TM) technology. TABWRAP(TM) is a
patented, high-speed continuous process for delivering tablets or caplets
in an ingestible or edible film sheet. It is applicable to a broad range of
product applications, including prescription and over-the-counter
pharmaceuticals.
Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are
pleased that BioProgress has selected to team up with Inyx to assist in the
validation requirements and commercialization of its TABWRAP(TM)
technology. We look forward to a growing collaboration with BioProgress."
Richard Trevillion, Chief Executive Officer of BioProgress, said, "Inyx
has a long history of assisting companies and innovative pharmaceutical
technologies with the required regulatory approvals on production processes
and controls. We are confident that BioProgress will be able to accelerate
its own development plan during 2007 through this strategic alliance with
Inyx."
About TABWRAP(TM)
TABWRAP(TM) handles a wide range of tablets sizes and shapes and treats
them individually, making it an ideal solution for fragile tablet
formulations. TABWRAP(TM) also eliminates the familiar problems of tablet
clumping, picking and sticking. TABWRAP(TM) utilizes XGEL(TM) films, the
basis of BioProgress' intellectual property and used in its film systems
and ingestible dosage-delivery technologies. All film formulations are
non-animal derived and tailored to provide specific product release rates
or stability requirements. XGEL(TM) films may be opaque, colored, printed,
flavored and contain actives and can have a high-gloss appearance. Single
or multiple color tablets can be produced economically by simply varying
the film properties. TABWRAP(TM) generates a skin-tight coating, which
adopts any underlying tablet embossing. A tamper-evident seal is generated
that helps protect the tablet core, often improving product stability.
TABWRAP(TM) is a dry process, so additional drying operations are
unnecessary. Production speeds in excess of 100,000 tablets per hour are
possible.
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and
healthcare business based around its enabling drug-delivery technologies in
polymer and film systems. Listed on London's AIM in May 2003 and on U.S.
Nasdaq in October 2004, the company has over 80 patents granted or in
application within 24 patent families and has product development
agreements and strategic alliances with several global companies. As a
virtually integrated business, BioProgress has acquired sales and marketing
resources within Europe and the U.S. as a launch mechanism for its own
pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL(TM) polymer technology, replacing the
need to use animal-derived gelatin in pharmaceutical and healthcare
products. For more information, visit:
About Inyx
Inyx, Inc. is a specialty pharmaceutical company with niche
drug-delivery technologies and products for the treatment of respiratory,
allergy, dermatological, topical and cardiovascular conditions. Inyx
focuses its expertise on both prescription and over-the-counter
pharmaceutical products, and provides specialty pharmaceutical development
and production consulting services. In addition, Inyx is developing its own
proprietary products. The company's operations are conducted through
several wholly owned subsidiaries: Inyx USA Ltd., based in Manati, Puerto
Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates
Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada,
Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania, which
conducts Inyx's marketing and distribution activities. Inyx, Inc.'s
corporate offices are in New York City. For more information, visit:

Safe Harbor
Statements about the Inyx's future expectations, including future
revenues and earnings, and all other statements in this press release other
than historical facts, are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. Inyx intends that such forward-looking
statements be subject to the safe harbors created thereby. Since these
statements involve risks and uncertainties and are subject to change at any
time, Inyx's actual results could differ materially from expected results.
For more information, please contact:

For Inyx:
Jay M. Green, Executive VP, 212-838-1111 jgreen@inyxgroup.com
Bill Kelly, VP, Investor Relations, 212-838-1111 bill.kelly@inyxgroup.com

For BioProgress:
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO
011-44-207-098-9881

Buchanan Communications
Rebecca Skye Dietrich/Mark Court
011-44-207-466-5000



SOURCE Inyx, Inc.